Non-invasive prenatal RHD genotyping using cell-free fetal DNA from maternal plasma: An Italian experience

Transfusion Medicine and Hemotherapy

Volumn 42, Issue 1, 2015, Pages 22-28

  Picchiassi, Elena ^a   Di Renzo, Gian Carlo ^a   Tarquini, Federica ^a   Bini, Vittorio ^a   Centra, Michela ^a   Pennacchi, Luana ^a   Galeone, Fabiana ^a   Micanti, Mara ^a   Coata, Giuliana ^a  

^a SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

Author keywords

Fetal DNA; Hemolytic disease of the fetus and newborn; Prenatal RHD genotyping

Indexed keywords

DNA;

ADULT; ARTICLE; BLOOD SAMPLING; CELL FREE FETAL DNA; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; EXON; EXPERIENCE; FALSE POSITIVE RESULT; FEMALE; FETUS; FIRST TRIMESTER PREGNANCY; GENE; GENE REPLICATION; GENOTYPING TECHNIQUE; GESTATIONAL AGE; HUMAN; MAJOR CLINICAL STUDY; MATERNAL BLOOD; MATERNAL PLASMA; NON INVASIVE PROCEDURE; PREDICTIVE VALUE; PREGNANT WOMAN; PRENATAL DIAGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; RHESUS D 5 ANTIBODY GENE; RHESUS D 7 ANTIBODY GENE; RHESUS D ANTIBODY GENE; RHESUS INCOMPATIBILITY; SENSITIVITY AND SPECIFICITY;

EID: 84925014402     PISSN: 16603796     EISSN: 16603818     Source Type: Journal    
DOI: 10.1159/000370233     Document Type: Article

References (29)

1. Rouillac-Le Sciellour C, Srazin V, Brossard Y, Oudin O, Le Van Kim C, Colin Y, Guidicelli Y, Menu M, Cartron JP: Noninvasive fetal RHD genotyping from maternal plasma. Use of a new developed Free DNA Fetal Kit RhD. Transfus Clin Biol 2007; 14: 572-577.
2. Finning KM, Martin PG, Soothill PW, Avent ND: Prediction of fetal D status from maternal plasma: introduction of a new noninvasive fetal RHD genotyping service. Transfusion 2002; 42: 1079-1085.
3. Costa JM, Giovangrandi Y, Ernault P: Foetal RHD genotyping in maternal serum during the first trimester of pregnancy. Br J Haematol 2002; 119: 255-260.
4. Gautier E, Benachi A, Giovangrandi Y: Fetal RhD genotyping by maternal serum analysis: a two-year experience. Am J Obstet Gynecol 2005; 192: 666-669.
5. Finning K, Martin P, Summers J, Massey E, Poole G, Daniels G: Effect of high throughput RHD typing of ffDNA in maternal plasma on use of anti-RhD immunoglobulin in RhD negative pregnant women: prospective feasibility study. BMJ 2008; 336: 816-818.
6. Sbarsi I, Isernia P, Montanari L, Badulli C, Martinetti M, Salvaneschi L: Implementing non-invasive RHD genotyping on cell-free foetal DNA from maternal plasma: the Pavia experience. Blood Transfus 2012; 10: 34-38.
7. Lo YM, Hjelm NM, Fidler C: Prenatal diagnosis of fetal RhD status by molecular analysis of maternal plasma. N Engl J Med 1998; 339: 1734-1738.
8. van der Schoot CE, Ait Soussan A, Dee R, Bonsel GJ, de Haas M: Screening for foetal RhD-genotype by plasma PCR in all D-negative pregnant women is feasible. Vox Sang 2004; 87(suppl):9.
9. Müller SP, Bartels I, Stein W: The determination of the fetal D status from maternal plasma for decision making on Rh prophylaxis is feasible. Transfusion 2008; 48: 2292-2301.
10. Van der Schoot CE, Soussan AA, Koelewijn J: Non-invasive antenatal RHD typing. Transfus Clin Biol 2006; 13: 53-57.
11. Clausen FB, Christiansen M, Steffensen R, Jorgensen S, Nielsen C, Jakobsen MA, Madsen RD, Jensen K, Krog GR, Rieneck K, Sprogie U, Homburg KM, Grunnet N, Dziegiel MH: Report of the first nationally implemented clinical routine screening for fetal RHD in D-pregnant women to ascertain the requirement for antenatal RhD prophylaxis. Transfusion 2012; 52: 752-758.
12. Moise KJ Jr, Boring NH, O'Shaughnessy R, Simpson LL, Wolfe HM, Baxter JK, Polzin W, Eddleman KA, Hassan SS, Skupski D, McLennan G, Paladino T, Oeth P, Bombard A: Circulating cell-free fetal DNA for the detection of RHD status and sex using reflex fetal identifiers. Prenat Diagn 2013; 33: 95-101.
13. Akolekar R, Finning K, Kuppusamy R, Daniels G, Nicolaides KH: Fetal RHD genotyping in maternal plasma at 11-13 weeks of gestation. Fetal Diagn Ther 2011; 29: 301-306.
14. Sedrak M, Hashad D, Adel H, Azzam A, Elbeltagy N: Use of free fetal DNA in prenatal noninvasive detection of fetal RhD status and fetal gender by molecular analysis of maternal plasma. Genet Test Mol Biomarkers 2011; 15: 627-631.
15. Cardo L, Garcia BP, Alvarez FV: Non-invasive fetal RHD genotyping in the first trimester of pregnancy. Clin Chem Lab Med 2010; 48: 1121-1126.
16. Bianchi DW, Avent ND, Costa JM, van der Schoot CE: Noninvasive prenatal diagnosis of fetal Rhesus D: ready for Prime(r) Time. Obstet Gynecol 2005; 106: 841-844.
17. Legler TJ, Liu Z, Mavrou A: Workshop report on the extraction of foetal DNA from maternal plasma. Prenat Diagn 2007; 27: 824-829.
18. Metcalfe P, Rigsby P, Tait E, Urbaniak S: An international reference reagent for the detection of RHD and SRY DNA in plasma. Vox Sang 2012; 102: 243-249.
19. Picchiassi E, Coata G, Fanetti A, Centra M, Pennacchi L, Di Renzo GC: The best approach for early prediction of fetal gender by using free fetal DNA from maternal plasma. Prenat Diagn 2008; 28: 525-530.
20. Macher HC, Noguerol P, Medrano-Campillo P, Garrido-Márquez MR, Rubio-Calvo A, Carmona-González M, Martin-Sánchez J, Parez-Simon JA, Guerrero JM: Standardization non-invasive fetal RHD and SRY determination into clinical routine using a new multiplex RT-PCR assay for fetal cell-free DNA in pregnant women plasma: results in clinical benefits and cost saving. Clin Chim Acta 2012; 413: 490-494.
21. Rijnders RJ, Christiaens GC, Bossers B, van der Smagt JJ, van der Schoot CE, de Haas M: Clinical applications of cell-free fetal DNA from maternal plasma. Obstet Gynecol 2004; 103: 157-164.
22. DeLong ER, DeLong DM, Clarke-Pearson DL: Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988; 44: 837-845.
23. Geifman-Holtzman O, Grotegut CA, Gaughan JP: Diagnostic accuracy of noninvasive fetal Rh genotyping from maternal blood - a meta-analysis. Am J Obstet Gynecol 2006; 195: 1163-1173.
24. Gunel T, Kalelioglu I, Gedikbasi A, Ermis H, Aydinli K: Detection of fetal RHD pseudogene (RHDφ) and hybrid RHD-CE-Ds from RHD-negative pregnant women with a free DNA fetal kit. Genet Mol Res 2011; 10: 2653-2657.
25. Silvy M, Chapel-Fernandes S, Callebaut I, Beley S, Durousseau C, Simon S, Lauroua P, Dubosc-Marchenay N, Babault C, Mouchet C, Ferrera V, Chiaroni J, Bailly P: Characterization of novel RHD alleles: relationship between phenotype, genotype, and trimeric architecture. Transfusion 2012; 52: 2020-2029.
26. Rouillac-Le Sciellour C, Puillandre P, Gillot R: Largescale pre-diagnosis study of fetal RHD genotyping by PCR on plasma DNA from RhD-negative pregnant women. Mol Diagn 2004; 8: 23-31.
27. Benachi A, Delahaye S, Leticee N, Jouannic JM, Ville Y, Costa JM: Impact of non-invasive fetal RhD genotyping on management costs of rhesus-D negative patients: results of a French pilot study. Eur J Obstet Gynecol Reprod Biol 2012; 162: 28-32.
28. Kenny-Walsh E: Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 1999; 340: 1228-1233.
29. Doescher A, Petershofen EK, Wagner FF, Schunter M, Müller TH: Evaluation of single-nucleotide polymorphisms as internal controls in prenatal diagnosis of fetal blood groups. Transfusion 2013; 53: 353-362.